LAB May 2024 5.000 call
| Previous Close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.3000 |
| Strike | 5.00 |
| Expire Date | 2024-05-17 |
| Day's Range | 0.0500 - 0.0500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 368 |
Insider MonkeyStandard BioTools Inc. (NASDAQ:LAB) Q1 2024 Earnings Call Transcript
Standard BioTools Inc. (NASDAQ:LAB) Q1 2024 Earnings Call Transcript May 11, 2024 Standard BioTools Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and welcome to the Standard BioTools Inc. First Quarter 2024 Earnings Conference Call. All participants […]
GlobeNewswireStandard BioTools Reports First Quarter 2024 Financial Results
Ahead of plan on operating expense synergies; $50 million of $80 million target to be achieved by year-end 2024 with remaining balance in FY2025Delivered pro forma combined revenue of $46.2 million, gross margin of 49.2%, non-GAAP gross margin of 56.3%, operating expense reduction of approximately $21 million, and non-GAAP operating expense reduction of approximately $17 millionOn track to cash flow positive in full-year 2026 with current balance sheet of $464 million cash, cash equivalents, res
- GlobeNewswire
Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth
Company expects to achieve $45-$50 million in annualized operating expense savings in fiscal 2025Management to discuss first quarter 2024 financial results, restructuring and strategic initiatives on May 8, 2024 conference call SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has initiated a restructuring plan to improve operational efficiency and reduce operating costs, while suppo
